[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-ischaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-ischaemia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,77,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100602228","positron-emission-tomography-to-assess-the-effect-of-camzyos-on-ischaemia-in-hocm-peach-trial-100602228",false,"NCT07120776","Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial","Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in Hypertrophic Obstructive Cardiomyopathy: The PEACH Trial","PEACH","Inclusion Criteria:\n\n1. Written informed consent.\n2. Aged 18 and over.\n3. Confirmed diagnosis of Hypertrophic Obstructive Cardiomyopathy (HOCM) based on diagnostic criteria, such as unexplained left ventricular hypertrophy with a maximal wall thickness ≥15 mm in the absence of uncontrolled hypertension, valvular heart disease, or HCM phenocopies such as amyloidosis and storage disorders, and presence of either a resting or provoked peak left ventricular outflow tract (LVOT) gradient ≥30 mmHg.\n4. Symptoms suggestive of myocardial ischaemia (chest pain, shortness of breath on exertion) with a clinical indication for Rb-PET.\n5. Eligible for Mavacamten treatment according to standard clinical guidelines. \\[see: https:\u002F\u002Fwww.nice.org.uk\u002Fguidance\u002Fta913\u002Fchapter\u002F1-Recommendations\\]. Mavacamten is part of participants' regular clinical treatment and is not being supplied, administered, or influenced by the study in any way.\n6. PET-CT performed for clinical reasons at any time in the preceding 18 months if reported as abnormal.\n\nExclusion Criteria:\n\n1. Patients with obstructive coronary artery disease (epicardial coronary stenosis \\>50%, assessed by either invasive coronary angiography or computed tomography angiography (CTCA). Patients will undergo the initial PET study as part of their routine clinical care. If evidence of ischaemia is identified, the standard next step would involve either CT coronary angiography or, in some cases, invasive angiography to guide further clinical management. If the angiography reveals a clear lesion responsible for the ischaemia identified on PET, the patient will not be eligible for inclusion in the study and will not be approached. Conversely, if the angiography does not identify a definitive cause for the ischaemia, it will be presumed to be of microvascular origin. In such cases, the patient becomes eligible for the study and will be approached to discuss participation and provide consent at this stage. It is important to emphasize that any angiographic procedure occurs prior to consent and as part of routine clinical care. No angiographic investigations are planned or conducted as part of the study protocol. Data from the clinical angiogram will not be included in the study, except to note a 'positive angiogram' as a reason for patient exclusion.\n2. Contraindications to Mavacamten, including left ventricular ejection fraction (LVEF) less than 55%, hypersensitivity or allergic reaction to the drug.\n3. Contraindication to Rubidium PET-CT, including:\n\n   * Pregnancy or breastfeeding.\n   * Severe claustrophobia.\n   * Morbid obesity when the patient dimensions are beyond the scanning chamber capacity.\n4. Any medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his\u002Fher participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.","ALL","18 Years",{"count":20,"type":21},75,"ESTIMATED","INTERVENTIONAL",[24],"NA","Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition that leads to the thickening of the heart muscle and causes obstruction of blood flow, impeding it's ejection from the heart (LVOT obstruction). Often individuals with HOCM suffer from chest pain and shortness of breath due to lack of oxygen supply (ischaemia) to the heart muscle in the absence of blockages in the coronary arteries.\n\nDespite proven advances in treatment of LVOT obstruction with the novel medication Camzyos (Mavacamten), there is a limited understanding of its effect on myocardial ischaemia.\n\nThis study, called the PEACH Trial, is designed to assess whether Camzyos also improves blood supply (perfusion) to the heart muscle in patients with HOCM. A specialised imaging technique called Positron Emission Tomography\u002FComputed Tomography (PET-CT), using Rubidium-82 will be used to evaluate blood flow to the heart muscle before and after treatment. Camzyos is part of participants' regular clinical treatment and is not being supplied, administered, or influenced by the study in any way.\n\nParticipants with HOCM who are starting treatment with Camzyos as part of their clinical care will undergo a baseline PET-CT scan (if not already done), and a second scan after 12 months. The follow-up scan is done solely for research purposes. The scans will allow researchers to evaluate whether the medication improves myocardial perfusion in addition to relieving outflow obstruction.\n\nThe study is sponsored by the University of Manchester and funded by Bristol Myers Squibb. It will involve up to 75 participants recruited at Manchester University NHS Foundation Trust. The findings could help improve understanding of how Camzyos works and support personalised treatment approaches in HOCM.",[27,28,29],"Hypertrophic Obstructive Cardiomyopathy \\(HOCM\\)","Left Ventricular Outflow Tract Obstruction","Myocardial Ischaemia",[31,32,33,34,35,36,37,38,39,40],"Camzyos","Mavacamten","HOCM","HCM","Cardiac PET","Rubidium-82 PET-CT","Myocardial Perfusion","Nuclear cardiology","Left ventricular outflow obstruction","Cardiomyopathy","RECRUITING","2026-05-19",{"date":44,"type":45},"2026-05-22","ACTUAL",{"date":47,"type":45},"2026-03-26",{"date":49,"type":21},"2028-10",{"name":51,"class":52},"University of Manchester","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":53},"100502612","coronary-ct-derived-ffr-guided-strategy-versus-medical-therapy-100502612","NCT05824520","Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy","Coronary Computed Tomography-Derived Fraction Flow Reserve (FFR)-Guided Invasive Treatment Strategy (ITS) Versus Optimal Medical Therapy (OMT) Alone in Patient With Chronic Coronary Syndrome","ACCURATE II","Inclusion Criteria:\n\n* Age ≥ 18 years, with at least one vessel has CT-derived FFR≤0.80\n* Patients with chronic coronary syndromes\n* Signed written informed consent\n\nExclusion Criteria:\n\n* The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Contrast media (Patients with documented sensitivity to contrast media which can be effectively pre-medicated with steroids and diphenhydramine \\[e.g. rash\\] may be enrolled)\n* Prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)\n* Sinus arrhythmia, cardiogenic shock, or severe heart failure (NYHA≥III)\n* Inability or unwillingness to undergo CT scan or coronary angiography\n* Patients on hemodialysis or with severe hepatic or renal insufficiency\n* Left main coronary artery stenosis ≥ 50%\n* Target vessel total occlusion\n* Pregnancy or intention to become pregnant during the course of the trial\n* Patients with a life expectancy less than 2 years",{"count":63,"type":21},1066,[24],"The overall purpose of ACCURATE II trial is to compare the clinical outcomes of CT-derived FFR guided strategy versus medical therapy in patients with chronic coronary syndrome.",[67,29],"Coronary Artery Disease","2026-01-29",{"date":70,"type":45},"2026-02-02",{"date":72,"type":45},"2024-10-10",{"date":74,"type":21},"2032-10-20",{"name":76,"class":52},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100582871","clinical-application-study-of-wearable-multi-channel-electrocardiogram-acquisition-equipment-in-the-diagnosis-of-myocardial-ischemia-in-patients-with-suspected-chd-100582871","NCT06868940","Clinical Application Study of Wearable Multi-channel Electrocardiogram Acquisition Equipment in the Diagnosis of Myocardial Ischemia in Patients with Suspected CHD","Clinical Application Study of Wearable Multi-channel Electrocardiogram Acquisition Equipment in the Diagnosis of Myocardial Ischemia in Patients with Suspected Coronary Heart Disease","Inclusion Criteria:\n\n* To be eligible to participate in this study, a participant must meet all of the following criteria:\n\n  1. Age \\> 18 years old;\n  2. Patients suspected of having coronary heart disease with myocardial ischemia;\n  3. Capable of using wearable ECG monitoring devices properly;\n  4. Informed consent obtained from the patient.\n\nExclusion Criteria:\n\n* If a patient meets any of the following conditions, they will be excluded:\n\n  1. Hemodynamic instability;\n  2. Second to third-degree atrioventricular block, sustained ventricular tachycardia, ventricular fibrillation, severe sinus bradycardia (heart rate \\\u003C 40 beats\u002Fmin).\n  3. Known congenital heart disease, severe valvular heart disease, acute heart failure, and decompensated chronic heart failure;\n  4. Severe comorbidities: Other diseases expected to have a life expectancy of ≤12 months; bronchial asthma or severe liver and kidney dysfunction; history of severe renal or liver function abnormalities (glomerular filtration rate \\\u003C 30 ml\u002F(min·1.73²m²), liver failure, cirrhosis, portal hypertension, or active hepatitis), neutropenia, thrombocytopenia;\n  5. Allergy to adenosine;\n  6. Imaging failure, such as patient movement during the acquisition process or too rapid injection of the imaging agent.",{"count":85,"type":21},107,"OBSERVATIONAL","Backgroud: With the widespread application of artificial intelligence, sensor technology, and wearable technology in clinical and daily life, wearable devices have shown a promising application prospect and tremendous potential. Currently, both domestic and international clinical applications of wearable ECG devices for the diagnosis and treatment of coronary heart disease are mostly single-lead ECG wearable devices or simulated multi-lead wearable ECG monitoring devices, which are widely used in the diagnosis of arrhythmias such as atrial fibrillation. There is a lack of clinical diagnostic efficacy research on myocardial ischemia in coronary heart disease.\n\nAim: To investigate the diagnostic efficacy of wearable multi-channel ECG acquisition devices for myocardial ischemia in suspected CHD patients Methods：Assessing the sensitivity, specificity, and accuracy of wearable multi-channel ECG devices in diagnosing myocardial ischemia in coronary heart disease by comparing with the \"gold standard\" SPECT-MPI.The target recruitment is 107 suspected coronary heart disease myocardial ischemia patients.If patients do not meet the exclusion criteria, they will wear the wearable multi-channel ECG device for 7 days after enrollment, followed by a myocardial SPECT examination; there is no specific order for these examinations. After enrollment, baseline information of the patients (such as age, gender, height, weight, etc.), comorbidities (such as hypertension, diabetes, hyperlipidemia, chronic kidney disease, etc.), and auxiliary examination data (such as complete blood count, biochemistry, cardiac injury markers, BNP, echocardiography, wearable multi-channel ECG device data, SPECT-related examination data, such as ST-segment, total load score, total rest score, etc.) will be collected. The endpoint of this study is to evaluate the sensitivity, specificity, and accuracy of the wearable multi-channel ECG device in assessing myocardial ischemia in CHD.",[89,29,90],"Coronary Arterial Disease (CAD)","Wearable Electronic Devices","NOT_YET_RECRUITING","2025-03-05",{"date":94,"type":45},"2025-03-11",{"date":96,"type":21},"2025-03",{"date":98,"type":21},"2026-02",{"name":100,"class":52},"West China Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":111,"studyType":86,"phases":4,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":53},"100568236","implementation-of-a-standardized-algorithm-for-coronary-calcification-with-plaque-modification-100568236","NCT06678594","Implementation of a Standardized Algorithm for Coronary Calcification With Plaque Modification","Implementation of a Standardized Algorithm for CoronarY CaLcificatiOn With PlaquE Modification Using UltraSound Guidance to Improve Procedural and Clinical Outcomes (CYCLOPES)","CYCLOPES","Inclusion Criteria:\n\n1. Documented myocardial ischaemia.\n2. At least one moderate to severely calcified native coronary artery lesion confirmed by QCA and\u002For 60MHz HD IVUS, with the presence of significant calcium, ≥70% diameter stenosis by visual estimation (in a reference vessel diameter of ≥2.5mm and ≤4.0mm) and TIMI 3 flow at baseline that is suitable for PCI.\n\n   a. Significant calcium at the target lesion site is defined as either: i. The presence of radiopacities involving both sides of the arterial wall \\>10mm and involving the target lesion on angiography.\n\n   or ii. The presence of \\>270° arc of superficial calcium on HD intravascular imaging with a length \\>5mm or the presence of 360° arc of calcium on HD intravascular imaging. \\[1\\]\n3. It is possible to cross the calcified lesion with a coronary guidewire.\n4. Age ≥ 18 years.\n5. Patient is willing and able to comply with the study procedures and follow-up.\n\nExclusion Criteria:\n\n1. Patients with cardiogenic shock.\n2. ST-segment elevation myocardial infarction.\n3. Instent re-stenosis.\n4. Stent thrombosis.\n5. Coronary artery dissection.\n6. Chronic total occlusion in a major artery.\n7. Left ventricular ejection fraction ≤30%. Need for coronary artery bypass graft surgery.\n\n9\\. Documented allergy to everolimus or to any stent material 10. Any contraindication for dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for at least 3 months (except for patients on oral anticoagulation). 11. For female, pregnancy, breastfeeding or intend to become pregnant within 1 year 12. Life expectancy \\<1 year. 13. Participation in another study with an investigational product. 14. Inability to provide informed consent.",{"count":110,"type":21},500,"1 Year","In this study, the doctors will follow a set of rules that is called an algorithm. An algorithm is a step-by-step approach that doctors use to guide them when making decisions about the best way to treat their patients. Algorithms are useful because they help doctors decide on the best treatment approach based on the patient's individual circumstances and the best medical evidence available. The algorithm that is being used in this study is called a calcium modification algorithm and it will guide doctors when deciding on the best way to modify or break up the calcium in coronary arteries.\n\nIn this study, we aim to prove that the calcium modification algorithm, described above, safely and effectively guides doctors on the best way to modify calcium in patients' coronary arteries. By doing so, it will help doctors in making decisions about patients' treatment during their procedure. It will also help standardise care for patients, so patients receive the same treatment no matter what hospital they are in or what doctor is treating them.",[29,114,115],"Severely Calcified Coronary Stenoses","Coronary Calcification",[117,118,119,120,121,122],"calcium modification","coronary calcification","plaque modification","IVUS","Intravascular Ultrasound","calcium modification algorithm","2024-11-05",{"date":125,"type":45},"2024-11-07",{"date":127,"type":45},"2024-09-24",{"date":129,"type":21},"2027-03-23",{"name":131,"class":52},"Royal College of Surgeons, Ireland"]